🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

Trump chooses US COVID policy critic Bhattacharya to lead NIH

Published 11/26/2024, 08:54 PM
Updated 11/26/2024, 10:45 PM
© Reuters. FILE PHOTO: US President-elect Donald Trump speaks during a meeting with House Republicans at the Hyatt Regency hotel in Washington, DC, U.S. on November 13, 2024.     ALLISON ROBBERT/Pool via REUTERS/File Photo

(Reuters) -President-elect Donald Trump on Tuesday chose Stanford academic and U.S. COVID policy critic Jay Bhattacharya to run the National Institutes of Health, the country's top public funder of medical research with a budget of some $47.3 billion 

The NIH has been in the crosshairs of Robert F. Kennedy Jr., Trump's pick to lead the Department of Health and Human Services, which oversees the NIH.

The NIH director oversees 27 institutes and centers that conduct early stage research on everything from vaccines for emerging pandemic threats to targets for new drugs.

Just days before his nomination as HHS secretary, RFK Jr. said he would act quickly to fire 600 people at the NIH and replace them all with new hires. The agency employs nearly 20,000 people.

In addition to job cuts, Kennedy has said he aims to shift NIH's focus from infectious diseases such as COVID-19, to tackling potential cures for chronic diseases, such as diabetes.

Bhattacharya, a Stanford health policy professor and doctor, was an outspoken critic of the U.S. government's COVID-19 policies during the pandemic. Along with two other academics, he published the Great Barrington Declaration in October 2020, which called for a return to life as normal for those who were not vulnerable to the virus.

He sued the government afterward, alleging that it pressured social media platforms to censor his opinions.

Bhattacharya graduated from Stanford University School of Medicine in 1997 and received his doctorate from Stanford's Department of Economics in 2000, according to his resume.

© Reuters. FILE PHOTO: US President-elect Donald Trump speaks during a meeting with House Republicans at the Hyatt Regency hotel in Washington, DC, U.S. on November 13, 2024.     ALLISON ROBBERT/Pool via REUTERS/File Photo

During the COVID pandemic, Dr. Anthony Fauci, director of the NIH's National Institute of Allergy and Infectious Disease who served on President Trump's coronavirus task force, became a frequent target of Republicans for contradicting some of Trump's coronavirus policies and recommendations, leading to calls for his dismissal.

Francis Collins, the NIH director and Fauci's boss, defended Fauci in a July 2020 interview with STAT News, saying it was “unimaginable” to consider firing Fauci, as some Republicans had demanded. As a career federal employee, Fauci's job was shielded from political firings by federal civil service regulations, protections Trump has vowed to undo.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.